PMPRB
August 21, 2023
CAPDM Submission to the PMPRB's 2023 Interim Guidance Consultation
This submission is made on behalf of the Canadian Association for Pharmacy Distribution Management (CAPDM) in response to the 2023 Proposed Amendment to the Interim Guidance re: New Medicines (the Draft Guidance). CAPDM is supportive of the Committee’s decision to study the ongoing PMPRB reforms, including the specific aspects this consultation explores, and encourages holistic examination of drug pricing to ensure sustainable funding for Canada’s medication supply system. Without consideration of the costs of physical storage and delivery in contemplating drug pricing approaches, the current and considered reforms will further destabilize an already fragile drug supply system, making access to medications for Canadians, particularly those in rural and remote areas, more challenging.
CAPDM Submission to the PMPRB's 2023 Interim Guidance Consultation
April 28, 2022
CAPDM Submission to the Parliamentary HESA Committee re: PMPRB
This submission is made on behalf of members of the Canadian Association for Pharmacy Distribution Management (CAPDM), in advance of the May 2, 2023 HESA Committee meeting to inform the study of the PMPRB. CAPDM is supportive of the Committee’s decision to study the ongoing PMPRB reforms, which will have a significant unintended negative impact on core funding for Canada’s medication supply system. In light of the recent changes in leadership at the highest levels of PMPRB, we believe now is an opportune time to revisit the intentions of the proposed PMPRB reforms and hold an open discussion regarding the effects on the already-fragile drug supply and potential further weakening of infrastructure that enables national medication access.
CAPDM Submission to the Parliamentary HESA Committee re: PMPRB
December 5, 2022
CAPDM Submission to the PMPRB December 2022 Revised Guidelines Consultation
Submitted on behalf of the members of the Canadian Association for Pharmacy Distribution Management (CAPDM), CAPDM’s response to the PMPRB’s 2022 Consultation reflected that CAPDM members support medicine affordability, but not at the cost of accessibility. CAPDM urged the PMPRB to suspend the current consultation process, to undertake comprehensive consultation with all supply chain stakeholders, and to conduct impact assessments of the Draft Guidelines to inform and protect affordability and accessibility of medications for all Canadians.
CAPDM Submission to the PMPRB December 2022 Revised Guidelines Consultation
August 4, 2020
CAPDM Submission to the PMPRB June 2020 Revised Guidelines Consultation
On behalf of the members of the Canadian Association for Pharmacy Distribution Management (CAPDM), we would like to thank you for considering our concerns and recommendations submitted as part of the November 2019 Draft Guidelines consultation. We now submit for your consideration, as part of the consultations on the Revised Guidelines, further ideas to protect the sustainability of the drug distribution infrastructure. This infrastructure allows every patient in Canada equal and ready access to the medications they need, regardless of where they live.
CAPDM Submission to the PMPRB June 2020 Revised Guidelines Consultation
April 1, 2020
Government of Canada
PMPRB Draft Guidelines Consultation
On July 1, 2020, the amended
Patented Medicines Regulations will come into force. Changes to the PMPRB’s pricing Guidelines are necessary in order for the regulatory amendments to be implemented. On November 21, 2019, the PMPRB published a draft set of new Guidelines for consultation with stakeholders and the public. Extensive feedback was received and all
written submissions are now available on the
PMPRB website.
The PMPRB will be making significant changes to the draft Guidelines in response to the feedback it has received. At this time, the PMPRB intends to publish a revised draft set of Guidelines later this spring and will provide stakeholders and the public with a limited period of time in which to submit their views in writing prior to the Guidelines being finalized.
The PMPRB is monitoring the evolving situation regarding the Covid-19 virus in Canada very closely and will reassess whether the next steps it currently intends to take with respect to the revised set of draft Guidelines are appropriate and feasible closer to the date of their publication.
The PMPRB will continue to work with its stakeholders to ensure that a fully operational set of Guidelines is ready in time for the coming into force of the regulatory amendments. In the meantime, patentees can rest assured that the final Guidelines will include transitional measures which will provide them ample time to take the necessary steps to come into voluntary compliance with the relevant price ceilings for both new and existing patented medicines.
February 6, 2020
CAPDM Submission to the PMPRB Draft Guidelines Consultation
On behalf of its members, the Canadian Association for Pharmacy Distribution Management (CAPDM) and as part of the consultations surrounding the PMPRB Draft Guidelines, submitted a review of the projected impact of the proposed reform on the pharmaceutical distribution sector. It raised options, for PMPRB’s consideration, that would mitigate the unintended impact to CAPDM members and, more importantly, safeguard timely access to medications for Canadians, regardless of whether they live in remote or urban areas.
CAPDM Submission to the PMPRB Draft Guidelines Consultation